Investigating RIPK2 as an Essential Pan-Enterovirus Host Factor: Unveiling a Promising Target for Novel Antiviral Therapeutics
Enteroviruses are widespread pathogens implicated in acute illness and increasingly linked to chronic diseases such as type 1 diabetes. Despite their impact, no FDA-approved antiviral therapies exist for enterovirus infections. Resistance to direct-acting antivirals underscores the need for alternative strategies. Given enteroviruses’ dependence on host machinery, targeting host factors, particula
